Vaccination

A new method assessing the influenza A strain provides investigators a more detailed look at flu viruses.

A lead investigator explains the findings of how active choice intervention in patient's electronic health records helps to increase vaccination rates.

Overall, a new Florida State study found that 13-17 year-olds are behind all children in influenza vaccination rates.

Developed as part of a joint partnership between Sanofi and Merck, Vaxelis' commercial supply is not expected until 2020.

Preventative medicine dominated the focus for C difficile treatment; however, a new reactive therapy also emerged.

Catia Mato Ferreira, PhD, global medical lead of Medical Affairs at Pfizer discussed the preventive potential of the C difficile vaccine that is currently in development in a phase 3 trial.

Until recently, studies of systemic corticosteroids in pneumonia have yielded contradicting results, while studies in acute exacerbation of COPD have shown significant benefits.

With the FDA approval, Abbot now anticipates to offer new assays for use this fall.

The single-dose, oral therapy becomes the first new influenza antiviral with a novel mechanism of action approved by the FDA in nearly 20 years.

The vaccine is designed to help protect patients against a pair of both influenza A strain and B strain viruses. It is currently available in the US for the 2018-19 flu season.

Investigators find school-located influenza vaccination increased coverage and decreased school absence and influenza hospitalization.

New research suggests that flu vaccination setting is associated with vaccination timing.

Originally approved by the FDA in 2006, the vaccine prevents certain cancers and diseases caused by the 9 types of HPV covered by the vaccine—an expansion from its originally-approved prevention of 4 different types.

High-risk individuals, such as those with cardiopulmonary and other chronic conditions, are protected from flu-related hospitalizations with the vaccine.

An oral influenza vaccine tablet protects against virus as well or better than an injectable quadrivalent vaccine in phase 2 trial.

Updates in trivalent vaccines and vaccination clearance for egg-allergic patients were among the updated recommendations for pediatric influenza prevention and treatment this upcoming 2018-2019 flu season.

Less than one-third received both influnza and Tdap vaccination during their pregnancies, citing limited understanding or assurance of their benefits and safety.

Tumor regressions were observed in 2 of the first 4 evaluable patients in the ongoing phase 2 trial evaluating DPX-Survivac in combination with low dose cyclophosphamide and pembrolizumab.

Investigators found that active choice intervention correlated with a nearly 10% increased likelihood of patients receiving the seasonal flu vaccine.

New recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.

In a systematic review and meta-analysis, low-quality drugs are most prevalent low- to middle-income countries, and can cost up to $200 billion annually.

First-in-man phase 1 trial meets its primary endpoints by demonstrating safety and immunogenicity of a mutation-specific IDH1R132H peptide vaccine.

Roche's cobas test systems will now be able to screen multiple individual blood or plasma donations that have been pooled together.

The U.S. FDA has granted Fast Track designation to PaxVax for development of its vaccine for prevention of the chkungunya virus.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.